when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
drugs
Xtandi

drug

enzalutamide

Marketedupdated 5mo ago

by Alessa Therapeutics Inc

Approved

community read0 votes

🐶 often sniffed alongside

top 3

tagApproval112 co-mentions · 28 sources
drugXTANDI112 co-mentions · 28 sources
tagSmall Molecule56 co-mentions · 28 sources

indications

investigational

Prostate Cancer

all catalysts(28)

approval · 28

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

view all 28 catalysts →

Trials studying enzalutamide

phase3A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Canceractive not recruitingn=960
phase3An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)active not recruitingn=49
phase2Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Canceractive not recruitingn=15
phase3Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCactive not recruitingn=1,054
phase3A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.recruitingn=900
phase2A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCrecruitingn=123
phase2An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)active not recruitingn=168
phase2FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Canceractive not recruitingn=44

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 17, 2026

47 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (17)

Feb 23, 2037method-of-use (U-4104)US 12161628
Feb 23, 2037method-of-use (U-4104)US 12161628
Feb 23, 2037method-of-use (U-4101)US 12161628
Sep 11, 2033formulationUS 11839689
Sep 11, 2033formulationUS 11839689
Sep 11, 2033method-of-use (U-4314)US 12447128
Sep 11, 2033method-of-use (U-4365)US 12502357
Sep 11, 2033method-of-use (U-4365)US 12502357
Aug 13, 2027compositionUS 7709517316d
Aug 13, 2027compositionUS 7709517316d
Aug 13, 2027compositionUS 7709517316d
Aug 24, 2026method-of-use (U-3763)US 8183274
Aug 24, 2026method-of-use (U-3763)US 8183274
Aug 24, 2026method-of-use (U-3763)US 8183274
May 15, 2026method-of-use (U-3763)US 9126941
May 15, 2026method-of-use (U-3763)US 9126941
May 15, 2026method-of-use (U-3763)US 9126941

FDA exclusivities (3)

Nov 17, 2026I-926Indication (3y)47d
Nov 17, 2026I-926Indication (3y)47d
Nov 17, 2026I-926Indication (3y)47d

News(3)

Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
biopharma_dive · 1mo ago
Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Cancer
Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus on radium…
onclive · 4mo ago
GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
onclive · 4mo ago

brand

Xtandi

generic

enzalutamide

indication

Prostate Cancer

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 3h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?